菜单

CRO Services

Drug Development Expertise Empowering Research Services for Biologics

 

 

 

Bispecific antibodies (BsAbs) enable diverse therapeutic MOAs such as retargeting cytotoxic effector cells, modulating receptor activity, and selectively recognizing pathogenic cells. However, advancing bsAbs from concept to preclinical candidates remains challenging, requiring comprehensive insights and technical expertise at every stage.

 

This webinar will explore practical strategies for bsAb discovery, from lead identification and high-throughput (HTP) production to in vitro assays and in vivo studies. Through real-world case studies, we will highlight one-stop, modular solutions for bsAb design, screening, and functional characterization to support the development of next-generation bsAb therapeutics.

 

In this webinar, you will learn:

 

  • Advanced antibody discovery platforms for biology-driven lead identification
  • Innovative Quick ‘n’ Clean platform for HTP bsAb production, unlocking optimal pairings rapidly
  • Comprehensive in vitro functional assays across T-cell engagers (TCEs), immune checkpoint inhibitors, and autoimmune diseases
  • Extensive in vivo efficacy models and well-established PK/PD/Tox platforms delivering time- and cost-effective solutions

 

 

Webinar Details

 

Date: Thursday, May 22, 2025

Time: 8:00 AM PT | 11:00 AM ET | 3:00 PM GMT

 

 

Speaker:

 

 

 

Macy Jin, MD

Director, CRO Services

 

Dr. Macy Jin joined WuXi Biologics in April 2023 as a subject matter expert in Biotherapeutic Drug Discovery. She brings over 20 years of experience from Wyeth/Pfizer, where she advanced from individual contributor to group leader of display platforms and project team leader in antibody discovery, with a focus on oncology, autoimmune, and rare diseases. Macy has extensive technical expertise, including over 10 years in hybridoma and display-based antibody discovery platforms. She is also a key inventor of phage panning and screening strategies that led to the discovery of Marstacimab (Hympavzi), the first FDA-approved anti-TFPI antibody for Hemophilia in 2024.

Enter your information to watch the recording

 

Have specific questions about bispecific antibody discovery?

Reach out to our experts!